⭕🇺🇸 Watch Tiffany's NEW documentary "Hollywood Takeover" on Epoch TV: https://epochtim.es/hollywood15 “Hollywood Takeover: China’s Control in the Film Industry” is coming to the big screen in New York City this Saturday. It will screen at the Manhattan Film Festival on June 15 at 1 p.m.
The United States is rethinking its nuclear arsenal strategy, potentially reversing decades of effort to reduce its weapons count.
The European Parliament just wrapped up an enormous election. Several strident China critics secured seats for another term, and they're vowing to build up a stronger Europe to counter Chinese aggression.
A top-selling Western weight-loss drug is taking the Chinese market by storm. But local Chinese rivals are eager to grab a slice, fueled by an early patent expiry on the drug's active ingredient.
00:00 Intro 02:04 U.S. Weighs More Nuclear Arms to Counter China, Russia 03:12 U.S., S. Korea Coordinate Potential Nuclear Response 04:16 China Hawks Reelected to EU Parliament 06:00 EU to Unseal Tariffs Plan on Chinese Electric Cars 06:44 Turkey Will Impose 40% Tariff on Chinese Vehicles 07:24 China Creating Copycat Versions of Top-Selling Drugs 08:59 Netherlands: Dutch Ship Harassed by Chinese Jets 09:30 How Effective Will Biden's Border Order Be?
- Epoch Original Documentary DVDs: 🔵 'The Shadow State' documentary takes a deep dive into the environmental, social, and governance (ESG) industry. ORDER DVD: https://ept.ms/3XxcWir 🔵 'The Final War' Documentary DVD: https://bit.ly/41PTIWC
Welcome to China In Focus, I'm Tiffany Meyer. Our top story.
The U.S. is rethinking its nuclear arsenal strategy, potentially reversing decades of
effort to reduce the weapons count, what a White House official is warning about.
The European Union parliament just wrapped up an enormous election.
Several big China critics secured their seats for another term,
and they are vowing to build up a stronger Europe to counter Chinese aggression.
We want a Europe that can defend itself, dear friends.
And a top-selling Western weight loss drug is taking the Chinese market by storm,
but local Chinese rivals are eager to grab a slice,
fueled by an early patent expiry on the drug's active ingredient.
Welcome to China In Focus, I'm Tiffany Meyer. Before we turn to today's top story,
we'd like to share an announcement. NTD's original documentary, Hollywood Takeover,
China's Control in the Film Industry, is coming to the big screen in New York City this Saturday.
It will screen at the Manhattan Film Festival on June 15th at 1 p.m. Take a look.
Is it really just about money? Are there other parts at stake?
Chinese influence was playing into what we see in U.S. films.
China said you can't have that in there, and Hollywood listened.
This is insane. And we all know that their goal is global domination.
People have been brainwashed without knowing it.
That's this Saturday at 1 p.m. at the Manhattan Film Festival. Don't miss it.
Click the link down below to get your tickets.
The Biden administration is weighing whether to deploy more nuclear weapons.
That's to counter rising aggression from China and Russia. The details come from
comments by a White House official Friday during a meeting of the Arms Control Association.
Pranay Vani is the National Security Council's top arms control official. He said, quote,
more nuclear weapons are required to deter our adversaries and protect the American people and
our allies. Another official who serves on the Congressional Commission on the Strategic Posture
of the U.S. said China and Russia are on a very aggressive path to develop their nuclear forces.
A day after those comments, Beijing responded by accusing Washington of undermining nuclear
disarmament. The U.S. currently holds no more than 1,500 nuclear warheads under an agreement
inked with Russia in 2010. But Moscow suspended the deal last year. Meanwhile, the Chinese
Communist Party is rapidly expanding its nuclear arsenal. The Pentagon has warned that Beijing
could have more than 1,000 nuclear warheads by 2030. More on the weapons of mass destruction.
South Korea and the United States are working to coordinate an allied nuclear response in case of
potential war with North Korea. Senior defense officials from both sides held talks at the third
nuclear consultative group in Seoul. It sets up the architecture for what eventually the NCG
provides oversight on, which will be the development of CNI options, concepts and
options that we can ultimately provide to our leaderships in a crisis. The U.S. has promised
to give South Korea more insight into its nuclear planning in case of a conflict with the North.
Draft guidelines lay out the principles and procedures for maintaining and enhancing
a credible and effective nuclear deterrent. The talks come as North Korea races ahead to
advance its nuclear weapons program and delivery systems. The developments have
triggered questions in South Korea about its reliance on the American nuclear umbrella.
The EU Parliament just wrapped up its elections, totaling 27 countries on Sunday.
Some of the continent's top China critics have secured their seats in parliament.
NTD's Flora Hua has more. The European Commission's ruling party, the EPP,
won with significant success. The party is EU Commission President Ursula von der Leyen's party,
and it continues to be the largest in parliament, with seven additional seats gained this year.
We want a Europe that can defend itself. The party's victory is also a boost of confidence
for the EU's top leader as she seeks another five-year term. She vows to enhance Europe's
defensibility and dealings with China. On von der Leyen's China agenda,
the country's unfair trade practices. Last month, she called on the Chinese leader Xi Jinping
to address China's overcapacity issue as soon as possible. She also launched an anti-subsidy
investigation into China's electric vehicle last October. Beyond von der Leyen's bid for re-election,
some of the most active China hawks in the EU parliament have just secured new terms of their
own. This includes a French member of parliament who led a forced labor ban targeting Beijing's
human rights abuses, a Slovak member who was sanctioned by Beijing three years ago,
and the former Dutch cybersecurity chief who spent most of his last term investigating China's
involvement in key European infrastructure. One official from Germany known for fearing
ties with China also got re-elected. He's under investigation for possible links to Beijing.
The European Union is expected to unseal a tariff plan on Chinese electric vehicles this week.
This comes as the bloc's automakers cope with an influx of cheap electric cars from the communist
country. EU officials have been probing China state subsidies for automakers. They believe
the financial benefits are behind a massive dumping trend of cheap products into the European
market. China's Ministry of Commerce said Thursday that Beijing is willing to sort out trade disputes
with the EU through dialogue. Over in the US, the White House announced a series of swiping
sanctions on 18 billion dollars worth of imports from China. That includes a 100% tariff on all
Chinese EVs. Turkey is set to impose a 40% tariff on imported Chinese vehicles. The country says
the tax will protect its domestic auto market and maintain its government account balance.
The number of countries are imposing tariffs on Chinese-made electric cars.
They say automakers in China are heavily subsidized by Beijing and that those state
benefits give Chinese carmakers an unfair advantage. Turkey already imposed additional
tariffs on Chinese electric vehicles last year. Turkey plans to charge at least seven thousand
dollars in new tariffs for each Chinese vehicle and they apply to conventional hybrid and electric
vehicles. Chinese drug makers are taking on a western pharma group's blockbuster medication.
At least 15 generic versions of popular weight loss and diabetes drugs Ozempic and Wegovy
are being developed in China. Here's a closer look.
Novo Nordisk, maker of blockbuster drug Ozempic, may face serious competition in China. The Danish
company had high hopes that the drug would boom in the promising Chinese market. In 2021, Ozempic
won approval from China and last year Novo Nordisk saw sales of the drug there double to almost 700
million dollars. It's expecting Wegovy to be approved this year. But the patent on semaglutide,
the active ingredient in both medicines, expires in China in 2026, which is far ahead of the
expiry in other key markets like Japan, Europe and the US. Novo is in a legal fight over the patent
in China, but an adverse court ruling could mean the company loses its semaglutide exclusivity
even sooner. Those circumstances have drawn several of the country's drug makers to the fray.
Records show at least 11 semaglutide drug candidates from Chinese firms are in the final
stages of clinical trials. And one company said it has developed a drug that has, quote,
similar clinical efficacy and safety as Ozempic. In April, it applied for approval for sale, which
it has said could come in the second half of 2025, with plans to sell the drug the following year.
That's unless Novo loses its patent battle sooner. A Dutch vessel reportedly harassed by Chinese
fighter jets. According to the Netherlands Defense Ministry, several Chinese aircraft
circled a Dutch warship and approached a patrol helicopter. The ship had been enforcing United
Nations sanctions on North Korea at the time. Officials said the maneuver caused a, quote,
potentially unsafe situation. The incident took place in the East China Sea, an international
shipping lane located between China, South Korea and Japan. How is illegal immigration
affecting life in America? President Biden recently passed an executive order meant to
limit the number of asylum seekers to 2,500 a day. Earlier, we spoke with NTD News contributor
A. Scott Bolden about the issue. Bolden is the former chair of the D.C. Democratic Party and
the former New York assistant district attorney. A. Scott Bolden, thank you so much for joining
us. Great to have you back on the show. Thank you for having me. Now, President Biden took
executive action. First, what is your view on this and how effective it will be?
Well, you know, I don't think Biden had much choice with the bipartisan legislation. It's a
good thing to get some control over the border, but it's not going to be enough. One, we need
Mexico to cooperate in repatriating many of these immigrants from other countries either to Mexico
or from Mexico. And then we need money. I mean, we need that. That's the congressional piece to it.
Need money to hire more judges, more security on the border, more technology. And Congress just is
unwilling to do that during the election year. But this is a good, strong first step. Surprisingly,
the Republicans aren't applauding it. You would think they would applaud it because they've been
pushing the president to do this. They haven't so far. They say it's too little too late. So
I don't think Joe Biden's going to have a win with the Republican Party one way or the other.
How do we ensure that legal immigration does continue while putting a stem to the
illegal immigration part? Well, we've got to encourage people to come through the port
sites legally. That's one thing. Secondly, we've got to have a strong partnership,
a stronger partnership with Mexico to enforce laws against the cartels, not just for illegal
immigration, if you will, but for drugs, as well as for people on the terrorist watch list. And,
you know, the majority of the people coming across the border are not from Mexico. You have
people coming across the border from the Middle East, from China, and at least one other South
American country. And so this is a real challenge for our Border Patrol people, which is why the
money is so important to protect that border, if you will, and to protect the northern border, too.
We don't talk about the northern border. If you talk to Canadian officials and border states
on the northern border, law enforcement and immigration officers will say,
we've got the same challenge. We're just not talking about the northern border.
Indeed. A. Scott Bolden, thank you so much for your time.
Thank you.
That's all for today's China InFocus on YouTube. We're now sharing a shortened version of our
program here after being demonetized for three years. If you'd like to support us, consider
donating. Find us at donorbox.org slash china-in-focus, or subscribe to our partner platform
Epic TV, where you can watch our full episodes. Just click the link down below.
Here's what to look out for in our second half.
Online shoppers, beware. Your next orders from Xi'an or Chimu could get stuck in U.S. customs.
A new U.S. regulation is causing speed bumps for no tariff shipments.
But that's not the only problem for Xi'an. The Chinese fast fashion brand is also hitting road
blocks in its quest to grow in Europe. European trade associations say they are worried about a
hidden threat lurking within Xi'an's budget-friendly offerings.
Fierce dragons, cultural maidens, and inspired music, all in the setting of a magical European
city. Catch a glimpse of the Tiangu marching band parade and its message after the break
here on China InFocus. Thanks for watching China InFocus. I'm Tiffany Meyer. See you tomorrow.